Tempest Q3 2021 Earnings Report
Key Takeaways
Tempest Therapeutics reported a net loss of $8.1 million, or $1.21 per share, for the third quarter of 2021. The company ended the quarter with $59.8 million in cash and cash equivalents. Research and development expenses were $4.6 million, and general and administrative expenses were $3.1 million.
Dosed first patients in first line, randomized, global Phase 1b/2 hepatocellular carcinoma (HCC) study of TPST-1120 combination regimen, in collaboration with F. Hoffmann La Roche.
In-licensed exclusive rights to novel oncology target from the lab of Russell Vance, Ph.D., at the University of California at Berkeley (U.C. Berkeley).
Continued enrollment in TPST-1495 monotherapy dose optimization towards recommended Phase 2 dose.
Commenced first line, randomized global Phase 1b/2 study in HCC patients, under a collaboration with F. Hoffmann La Roche for TPST-1120.
Tempest
Tempest
Forward Guidance
Tempest expects to have sufficient resources to fund operations into the second quarter of 2023.